Kura Oncology (KURA) Cash & Equivalents: 2024-2025
Historic Cash & Equivalents for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $95.3 million.
- Kura Oncology's Cash & Equivalents rose 92.58% to $95.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.3 million, marking a year-over-year increase of 92.58%. This contributed to the annual value of $224.5 million for FY2024, which is N/A change from last year.
- Per Kura Oncology's latest filing, its Cash & Equivalents stood at $95.3 million for Q3 2025, which was up 16.28% from $81.9 million recorded in Q2 2025.
- In the past 5 years, Kura Oncology's Cash & Equivalents registered a high of $224.5 million during Q4 2024, and its lowest value of $41.5 million during Q1 2024.
- Over the past 2 years, Kura Oncology's median Cash & Equivalents value was $51.3 million (recorded in 2025), while the average stood at $84.2 million.
- Data for Kura Oncology's Cash & Equivalents shows a peak YoY spiked of 92.58% (in 2025) over the last 5 years.
- Over the past 2 years, Kura Oncology's Cash & Equivalents (Quarterly) stood at $224.5 million in 2024, then soared by 92.58% to $95.3 million in 2025.
- Its Cash & Equivalents was $95.3 million in Q3 2025, compared to $81.9 million in Q2 2025 and $51.3 million in Q1 2025.